Polypharmacy Cut-Off for Gait and Cognitive Impairments

Antoine Langeard, Kristell Pothier, Remy Morello, Véronique Lelong-Boulouard, Pascale Lescure, Marie-Laure Bocca, Christian Marcelli, Pablo Descatoire, Chantal Chavoix, Antoine Langeard, Kristell Pothier, Remy Morello, Véronique Lelong-Boulouard, Pascale Lescure, Marie-Laure Bocca, Christian Marcelli, Pablo Descatoire, Chantal Chavoix

Abstract

Background: Polypharmacy is a well-established risk factor for falls, and these are one of the major health problems that affect the quality of life as people age. However, the risk of mobility and cognitive impairments consecutive to polypharmacy has been little addressed, despite the association between these adverse outcomes and falls. Moreover, the rare polypharmacy cut-offs were all but one arbitrarily determined.

Objective: Studying relationships between polypharmacy and both mobility and cognitive impairments, and statistically determining a cut-off point in the number of medicinal molecule beyond which polypharmacy has deleterious consequences with respect to mobility and cognitive impairment.

Methods: We enrolled 113 community-dwelling adults aged 55 years and older with a fall history, with or without injury, in the previous year. We carefully collected information about daily medicinal molecules taken. We assessed basic mobility and global cognition with the Time-Up-and-Go and the Montreal Cognitive Assessment (MoCA) test, respectively (clinicaltrials.gov NCT02292316).

Results: Timed-Up and Go test and MoCA scores were both significantly correlated with the number of molecule, used. Receiver Operating Characteristic curves indicate, with high prediction (p < 0.002), that daily consumption of five or more molecules is associated with risk for both impaired mobility and global cognition. These relationships were independent of the number of comorbidities and of the pharmacological class.

Conclusion: Community-dwelling adults aged 55 years and older who take five or more daily medicinal molecules are at high risk for both mobility and cognitive impairments. Physicians and patients should be aware of these new findings, especially when there are multiple prescribers involved in the care of the patient.

Keywords: aging; cognition; cut-off; gait; middle age; mobility; polypharmacy.

Figures

FIGURE 1
FIGURE 1
Each point on the ROC curve corresponds to a specific cut-off, with each cut-off having its own sensitivity and specificity. The optimal cut-off is defined as the value, here that of the number of molecules, that provides the best combination of sensitivity and specificity. This optimal cut-off can be identified as the intersection of the ROC curve with the diagonal. The area under the curve (AUC) is equal to 1 for perfect discrimination and 0.5 for an uninformative cut-off point. The optimal cut-off value of the number of molecules was 4.5 for each ROC curve. MoCA, Montreal Cognitive Assessment; TUG, Timed Up and Go test.

References

    1. Agostini J. V., Han L., Tinetti M. E. (2004). The relationship between number of medications and weight loss or impaired balance in older adults. J. Am. Geriatr. Soc. 52 1719–1723. 10.1111/j.1532-5415.2004.52467.x
    1. Ambrose A. F., Paul G., Hausdorff J. M. (2013). Risk factors for falls among older adults: a review of the literature. Maturitas 75 51–61. 10.1016/j.maturitas.2013.02.009
    1. Bennett A., Gnjidic D., Gillett M., Carroll P., Matthews S., Johnell K., et al. (2014). Prevalence and impact of fall-risk-increasing drugs, polypharmacy, and drug–drug interactions in robust versus frail hospitalised falls patients: a prospective cohort study. Drugs Aging 31 225–232. 10.1007/s40266-013-0151-3
    1. Bohannon R. W. (2006). Reference values for the timed up and go test: a descriptive meta-analysis. J. Geriatr. Phys. Ther. 2001 64–68. 10.1519/00139143-200608000-00004
    1. Chen Y., Zhu L.-L., Zhou Q. (2014). Effects of drug pharmacokinetic/pharmacodynamic properties, characteristics of medication use, and relevant pharmacological interventions on fall risk in elderly patients. Ther. Clin. Risk Manag. 10 437–448. 10.2147/TCRM.S63756
    1. Cummings S. R., Nevitt M. C., Kidd S. (1988). Forgetting falls. The limited accuracy of recall of falls in the elderly. J. Am. Geriatr. Soc. 36 613–616. 10.1111/j.1532-5415.1988.tb06155.x
    1. Farrell B., Merkley V. F., Thompson W. (2013). Managing polypharmacy in a 77-year-old woman with multiple prescribers. CMAJ 185 1240–1245. 10.1503/cmaj.122012
    1. Fried T. R., O’Leary J., Towle V., Goldstein M. K., Trentalange M., Martin D. K. (2014). Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J. Am. Geriatr. Soc. 62 2261–2272. 10.1111/jgs.13153
    1. Gnjidic D., Hilmer S. N., Blyth F. M., Naganathan V., Waite L., Seibel M. J., et al. (2012). Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J. Clin. Epidemiol. 65 989–995. 10.1016/j.jclinepi.2012.02.018
    1. Golden A. G., Preston R. A., Barnett S. D., Llorente M., Hamdan K., Silverman M. A. (1999). Inappropriate medication prescribing in homebound older adults. J. Am. Geriatr. Soc. 47 948–953. 10.1111/j.1532-5415.1999.tb01289.x
    1. Hartikainen S., Lönnroos E., Louhivuori K. (2007). Medication as a risk factor for falls: critical systematic review. J. Gerontol. A Biol. Sci. Med. Sci. 62 1172–1181. 10.1093/gerona/62.10.1172
    1. Johnell K., Klarin I. (2007). The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf. 30 911–918. 10.2165/00002018-200730100-00009
    1. Jyrkkä J., Enlund H., Lavikainen P., Sulkava R., Hartikainen S. (2011). Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol. Drug Saf. 20 514–522. 10.1002/pds.2116
    1. Kaplan M. H., Feinstein A. R. (1974). The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J. Chronic Dis. 27 387–404. 10.1016/0021-9681(74)90017-4
    1. Kojima T., Akishita M., Nakamura T., Nomura K., Ogawa S., Iijima K., et al. (2011). Association of polypharmacy with fall risk among geriatric outpatients. Geriatr. Gerontol. Int. 11 438–444. 10.1111/j.1447-0594.2011.00703.x
    1. Lai S.-W., Lin C.-H., Liao K.-F., Su L.-T., Sung F.-C., Lin C.-C. (2012). Association between polypharmacy and dementia in older people: a population-based case-control study in Taiwan. Geriatr. Gerontol. Int. 12 491–498. 10.1111/j.1447-0594.2011.00800.x
    1. Liu-Ambrose T. Y., Ashe M. C., Graf P., Beattie B. L., Khan K. M. (2008). Increased risk of falling in older community-dwelling women with mild cognitive impairment. Phys. Ther. 88 1482–1491. 10.2522/ptj.20080117
    1. Lu W.-H., Wen Y.-W., Chen L.-K., Hsiao F.-Y. (2015). Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study. CMAJ 187 E130–E137. 10.1503/cmaj.141219
    1. Nasreddine Z. S., Phillips N. A., Bédirian V., Charbonneau S., Whitehead V., Collin I., et al. (2005). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53 695–699. 10.1111/j.1532-5415.2005.53221.x
    1. Nobili A., Garattini S., Mannucci P. M. (2011). Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J. Comorbidity 1 28–44. 10.15256/joc.2011.1.4
    1. Pothier K., Benguigui N., Kulpa R., Chavoix C. (2014). Multiple object tracking while walking: similarities and differences between young, young-old, and old-old adults. J. Gerontol. B Psychol. Sci. Soc. Sci. 70 840–849. 10.1093/geronb/gbu047
    1. Pugh M. J. V., Palmer R. F., Parchman M. L., Mortensen E., Markides K., Espino D. V. (2007). Association of suboptimal prescribing and change in lower extremity physical function over time. Gerontology 53 445–453. 10.1159/000119460
    1. Tinetti M. E., Speechley M., Ginter S. F. (1988). Risk factors for falls among elderly persons living in the community. N. Engl. J. Med. 319 1701–1707. 10.1056/NEJM198812293192604
    1. Ziere G., Dieleman J. P., Hofman A., Pols H. A. P., van der Cammen T. J. M., Stricker B. H. C. (2006). Polypharmacy and falls in the middle age and elderly population. Br. J. Clin. Pharmacol. 61 218–223. 10.1111/j.1365-2125.2005.02543.x

Source: PubMed

3
Suscribir